To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Hydroxyurea or hydroxycarbamide (the latter being the recommended International Non-Proprietary Name), (brand names include Hydrea® and Droxia®) is an antineoplastic drug used in hematological malignancies. It is also used as an antiretroviral agent (e.g., against HIV).
Additional recommended knowledge
Its mechanism of action is believed to be based on its inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction NDPs.
500 milligrams once or twice a day, or more if pancytopenia does not develop.
Reported side-effects are: drowsiness, nausea, vomiting and diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (which may take 7-21 days to recover after the drug has been discontinued), alopecia (hair loss), skin changes, abnormal liver enzymes, creatinine and blood urea nitrogen.
Due to its effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked.
Use in pregnancy
Category D - investigational or post-marketing data show risk to the fetus. However, potential benefits may outweigh the potential risk. Generally this rating is reserved for drugs with no safer alternatives.
Contraindications are: severe anemia, bone marrow depression or neutropenia.
Categories: Chemotherapeutic agents | Ureas
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hydroxyurea". A list of authors is available in Wikipedia.|